Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location

Cancer

Volumn 119, Issue 16, 2013, Pages 3084-3091

  Golan, Talia ^a,b   Urban, Damien ^a,c   Berger, Raanan ^a,b   Lawrence, Yaacov Richard ^a,d  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

age; changing prognosis; metastatic colorectal cancer; overall survival

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CHILD; COLORECTAL CARCINOMA; DEMOGRAPHY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL ADENOCARCINOMA; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RACE; SCHOOL CHILD;

EID: 84881477253     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28143     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27: 663-671.
3. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345.
4. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-2947.
5. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 1041-1047.
6. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22: 23-30.
7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343: 905-914.
8. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229-237.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
10. Petrelli NJ, Abbruzzese J, Mansfield P, Minsky B,. Hepatic resection: the last surgical frontier for colorectal cancer. J Clin Oncol. 2005; 23: 4475-4477.
11. Pfannschmidt J, Dienemann H, Hoffmann H,. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007; 84: 324-338.
12. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH,. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309-318; discussion 318-321.
13. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG,. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008; 247: 125-135.
14. Murthy VH, Krumholz HM, Gross CP,. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291: 2720-2726.
15. Hankey BF, Ries LA, Edwards BK,. The Surveillance, Epidemiology, and End Results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999; 8: 1117-1121.
16. National Cancer Institute. Surveillance, Epidemiology, and End Results. SEER Stat software, version 7. Available at: http://seer.cancer.gov/seerstat/. Accessed March 2, 2012.
17. Grambsch PM, Therneau TM,. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515-526.
18. Hankinson TC, Fields EC, Torok MR, et al. Limited utility despite accuracy of the national SEER dataset for the study of craniopharyngioma. J Neurooncol. 2012; 110: 271-278.
19. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40: IV-3-18.
20. Zippin C, Lum D, Hankey BF,. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer. 1995; 76: 2343-2350.
21. Feinstein AR, Sosin DM, Wells CK,. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985; 312: 1604-1608.
22. Faivre J, Lemmens VE, Quipourt V, Bouvier AM,. Management and survival of colorectal cancer in the elderly in population-based studies. Eur J Cancer. 2007; 43: 2279-2284.
23. Mitry E, Bouvier AM, Esteve J, Faivre J,. Improvement in colorectal cancer survival: a population-based study. Eur J Cancer. 2005; 41: 2297-2303.
24. O'Connell JB, Maggard MA, Ko CY,. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004; 96: 1420-1425.
25. Le H, Ziogas, A, Lipkin, SM, Zell, JA,. Effects of socioeconomic status and treatment disparities in colorectal cancer survival. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1950-1962.
26. McKibbin T, Frei CR, Greene RE, Kwan P, Simon J, Koeller JM,. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist. 2008; 13: 876-885.
27. Kumar R, Jain K, Beeke C, et al. A population-based study of metastatic colorectal cancer in individuals aged ≥/80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer. Cancer. 2012.
28. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004; 15: 1330-1338.
29. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006; 24: 4085-4091.
30. Jehn CF, Boning L, Kroning H, Possinger K, Luftner D,. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer. 2012; 106: 274-278.
31. Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol. 2012; 23: 1531-1536.
32. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O,. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009; 27: 199-205.
33. Khattak MA, Townsend AR, Beeke C, et al. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. Eur J Cancer. 2012; 48: 1293-1298.
34. Papamichael D, Audisio R, Horiot JC, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol. 2009; 20: 5-16.
35. Survival of Cancer Patients in Europe: The EUROCARE-2 study. IARC Sci Publ. 1999: 1-572.
36. Surbone A, Kagawa-Singer M, Terret C, Baider L,. The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann Oncol. 2007; 18: 633-638.